Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
OtherArticle

Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans

Päivi Taavitsainen, Olaf Prien, Marja Kähkönen, Michael Niehues, Timo Korjamo, Karsten Denner, Pirjo Nykänen, Annamari Vuorela, Natalia A. Jungmann, Clemens-Jeremias von Bühler, Mikko Koskinen, Christian Zurth and Hille Gieschen
Drug Metabolism and Disposition March 30, 2021, DMD-AR-2020-000309; DOI: https://doi.org/10.1124/dmd.120.000309
Päivi Taavitsainen
1Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olaf Prien
2Bayer AG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marja Kähkönen
1Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Niehues
2Bayer AG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timo Korjamo
1Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karsten Denner
2Bayer AG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pirjo Nykänen
1Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annamari Vuorela
1Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalia A. Jungmann
3DMPK, Bayer AG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens-Jeremias von Bühler
2Bayer AG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikko Koskinen
1Orion Corporation Orion Pharma, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Zurth
2Bayer AG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hille Gieschen
4Research & Development, Pharmaceuticals, Bayer AG, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hille Gieschen
  • For correspondence: hille.gieschen@bayer.com
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

DMD-AR-2020-000309
DOI 
https://doi.org/10.1124/dmd.120.000309
PubMed 
33785516

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Published online March 30, 2021.

Copyright & Usage 
© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.

Author Information

  1. Päivi Taavitsainen1,
  2. Olaf Prien2,
  3. Marja Kähkönen1,
  4. Michael Niehues2,
  5. Timo Korjamo1,
  6. Karsten Denner2,
  7. Pirjo Nykänen1,
  8. Annamari Vuorela1,
  9. Natalia A. Jungmann3,
  10. Clemens-Jeremias von Bühler2,
  11. Mikko Koskinen1,
  12. Christian Zurth2, and
  13. Hille Gieschen4,*
  1. 1Orion Corporation Orion Pharma, Finland
  2. 2Bayer AG, Germany
  3. 3DMPK, Bayer AG, Germany
  4. 4Research & Development, Pharmaceuticals, Bayer AG, Germany
  1. ↵* Corresponding Author:
    Hille Gieschen, Research & Development, Pharmaceuticals, Bayer AG, Building M004, 435, Berlin, Germany. E-mail: hille.gieschen{at}bayer.com

Statistics from Altmetric.com

Article usage

Article usage: March 2021 to April 2021

AbstractFullPdf
Mar 2021200239
Apr 202137024217

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 49 (5)
Drug Metabolism and Disposition
Vol. 49, Issue 5
1 May 2021
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherArticle

Darolutamide human biotransformation and excretion

Päivi Taavitsainen, Olaf Prien, Marja Kähkönen, Michael Niehues, Timo Korjamo, Karsten Denner, Pirjo Nykänen, Annamari Vuorela, Natalia A. Jungmann, Clemens-Jeremias von Bühler, Mikko Koskinen, Christian Zurth and Hille Gieschen
Drug Metabolism and Disposition March 30, 2021, DMD-AR-2020-000309; DOI: https://doi.org/10.1124/dmd.120.000309

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherArticle

Darolutamide human biotransformation and excretion

Päivi Taavitsainen, Olaf Prien, Marja Kähkönen, Michael Niehues, Timo Korjamo, Karsten Denner, Pirjo Nykänen, Annamari Vuorela, Natalia A. Jungmann, Clemens-Jeremias von Bühler, Mikko Koskinen, Christian Zurth and Hille Gieschen
Drug Metabolism and Disposition March 30, 2021, DMD-AR-2020-000309; DOI: https://doi.org/10.1124/dmd.120.000309
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Humanized PXR-CAR-CYP3A4/7 Mouse as Model of Induction
  • Ozanimod Human Metabolism and Disposition
  • High-Throughput Characterization of SLCO1B1 VUS
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics